Papers by Jose Vicente Terencio · AgingResearch.News

Alzheimer's & Dementia13 Aug
Long-term safety and immunogenicity of ABvac40 active immunotherapy in mild cognitive impairment and very mild Alzheimer's disease: Results from AB1601 phase 2 extension study
Trial in peopleInterventions
Paper
AAIC 2025 Abstract26 Dec
Meaningful Clinical Impact of ABvac40 in Early‐Stage Alzheimer’s Disease: Results from the AB1601 Phase 2 Study
Trial in peopleInterventions
Paper
AAIC 2025 Abstract26 Dec
Integrating Plasma pTau‐217 and Aβ42/Aβ40 Ratio for Accurate Non‐Invasive Prediction of Brain Amyloid Accumulation
Study in peopleBiomarkers
Paper